NEW YORK, NY--(Marketwire - Dec 19, 2012) - Immunovative, Inc. ("IMUN" or the "Company") (OTCQB: IMUN) has today announced that the Company has been featured on the cover of the prestigious OPPORTUNIST MAGAZINE ("OPPORTUNIST" or "The Magazine") for the December 18, 2012 Edition (Link: http://opportunistmagazine.com/seth-m-shaw-chairman-and-ceo-of-immunovative-inc-name/). The Magazine is a weekly U.S. based publication with readership base of more than one million and thousands of shared links. The magazine is full of informative articles from financial and legal professionals who understand their public sector industries, as well as in-depth interviews with prominent business people, politicians and celebrities.
Immunovative CEO Seth Shaw commented, "We are pleased to have this opportunity to showcase our company and its merits in a quality publication with a large reader base. It is of great importance to the Company to both enhance public awareness and to increase the shareholder base."
About Immunovative, Inc.:
On December 12th, 2011, Immunovative, Inc. ("IMUN") signed an exclusive License Agreement (the "License Agreement") with Immunovative Therapies, Ltd. ("ITL"). Under the terms of the License Agreement, IMUN has been granted an exclusive, worldwide license to commercialize any products covered under ITL's current issued and pending patent application portfolio, as well as the rights to any future patent applications, including improvements or modifications to the existing applications and any corresponding improvements or new versions of the existing products. Please visit IMUN's website at www.imun.com.
About Immunovative Therapies, Ltd.:
Immunovative Therapies, Ltd. is an Israeli biopharmaceutical company that was founded in May 2004 with financial support from the Israeli Office of the Chief Scientist. ITL is a graduate of the Misgav Venture Accelerator, a member of the world-renowned Israeli technological incubator program. The company was the Misgav Venture Accelerator's candidate for the prize for the outstanding incubator project of 2006, awarded by the Office of the Chief Scientist. ITL specializes in the development of novel immunotherapy drug products that incorporate living immune cells as the active ingredients for treatment of cancer and infectious disease. Please visit ITL's website at: www.immunovative.co.il
About Opportunist Magazine:
Opportunist (http://www.opportunistmagazine.com) was known in the '90s as an extreme, cutting edge national stockbroker magazine profiling young maverick companies. In 2010 we came back on a fast track to once again become the leading source of optimism for investors. The magazine is full of informative articles from financial and legal professionals who understand their public sector industries, as well as in-depth interviews with prominent business people, politicians and celebrities. Our headquarters is in the Orlando area and we are currently an online publication -- with a 1 million + readership -- including a supplement inserted into the Wall Street Journal (to nearly one-half million of their home delivery subscribers).
Leslie Stone is an award-winning writer and the managing editor of Opportunist magazine. Each week she does an in-depth interview/cover story featuring a prominent business person, media personality, politician or celebrity.
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on IMUN's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which IMUN has little or no control. Such forward-looking statements are made only as of the date of this release, and IMUN assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by IMUN with the Securities and Exchange Commission.